Making DREAM(s) Come True Isn’t Easy



By John Russell

July 14, 2008 | How good is your algorithm for turning experimental data—mainly gene expression or protein interactions—into accurate pictures of biological networks?  If the results from the first DREAM challenge are any indication, plenty of progress is needed to improve pathway predictions from data.

The DREAM initiative—Dialogue for Reverse Engineering Assessments and Methods—is intended to help the life science community improve computational techniques for inferring networks. Datasets from known networks are provided and researchers are invited to uncover the true underlying networks using computational techniques. In this first “competition,” there were five challenges, 36 participating teams, and 110 predictions.

“DREAM is trying to understand whether we predict something meaningful when we take high-throughput data like gene expression and we say, well this is the network of interactions,” says one of DREAM’s organizers, Gustavo Stolovitzky. “Usually you validate with five or six connections that you either do in the lab or validate through literature. But actually you have made 1,000 predictions and you only cherry pick the five that match your data, so in a way, we don’t know whether we are fooling ourselves or whether really we have something in those predictions.”

On balance, this year’s predictions were lousy. Talking about one specific challenge, Stolovitzky says, “These were 200 genes of which 53 were true positives and the rest were not. Some people did well in the first 10 or 15, but then really not so well. At the same time many, many teams, some of which are very well known people that have one of these algorithms as their favorite algorithm [did very poorly] and their favorite algorithm is very bad, really bad, as bad as random so if you put a random predictor you will have predicted better.”

Predictions of protein interactions were even worse. Stolovitzky says simply, “If you, today, go with a set of proteins and sequences and you give it to someone who says, ‘I can predict which of these proteins are interacting,’ probably he is going to give you garbage. And that is a truth, but it is important to know that this is the case. It’s not to just roast the people who didn’t do well. It’s just to understand where we should improve.”

Ouch. Not surprisingly no commercial tool providers tackled the challenges. And let’s be clear—as Stolovitzky is—the idea isn’t to roast anyone. The goal is to learn which algorithms work best, to assist in developing better algorithms, and to help the entire community move forward. In releasing DREAM2 results, the names of the teams were not revealed.

Stolovitzky is adjunct associate professor of Biomed Informatics, Columbia University, and manager, Functional Genomics & Systems Biology, IBM Research. He notes that despite the poor results of the first set of challenges, much good work is being done by researchers using similar techniques.

Asked for his thoughts on recent work led by Merck researcher Eric Schadt in identifying key networks involved in metabolic disease by interpreting gene expression and other data (see “Merck’s Informatics Mission,” Bio-IT World, May 2008), he says, “They are great. I think he’s doing something that we all should be doing, and we are not doing in DREAM, which is he puts together a lot of [different kinds of] information like quantitative analysis, gene expression, and clinical information.”

Round Three
Plans are already afoot for DREAM3 which will be held in conjunction with 5th Annual RECOMB Satellite on Regulatory Genomics and the 4th Annual RECOMB Satellite on System Biology next October 29-Nov 2 (http://compbio.mit.edu/recombsat/). The meeting is jointly organized by the Broad Institute of MIT and Harvard, and the MIT Computer Science and Artificial Intelligence Lab (CSAIL). “We would like to cordially invite anyone to submit network inferences and answers to our new biological prediction challenges. To access the data sets and descriptions of the challenges, please go to http://wiki.c2b2.columbia.edu/dream/index.php/The_DREAM3_Challenges,” say Stolovitzky and DREAM3 co-organizer, Andrew Califano.

Interest in DREAM is growing, reports Stolovitzky. The International Society for Computational Biology is creating a team of students to participate in DREAM he says. He also says they will probably ask researchers if they want to be identified next year. Given the suggestion that some well-regarded researchers fared less well, this might by an opportunity for others to gain notice.

In any case, for the foreseeable future, consistent prediction of underlying networks from just a few data types and using only computational techniques is still something of a dream.

___________________________________________________

This article appeared in Bio-IT World Magazine.

Subscriptions are free for qualifying individuals.  Apply Today.

 

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .